SOURCE: Calypte Biomedical Corp.

July 13, 2007 09:30 ET

Calypte Biomedical Corporation's (OTCBB: CBMC) CEO, Roger Gale, Appearing Live via Web-Cam at on Friday, July 13th, 2007 at 3 PM EDT

LAKE OSWEGO, OR--(Marketwire - July 13, 2007) - Calypte Biomedical Corporation (OTCBB: CBMC), medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV), will talk about their new advancements live on

About Calypte Biomedical:

Calypte Biomedical Corporation ( is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware™ HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.


Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.

Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

Stay up to date with MN1 NewsWire "News You Can Trust" at

Safe Harbor Statement:

This news release includes forward-looking statements regarding, among other things, the Company's business, financial plans, strategies and prospects. Although the Company believes that its plans and expectations reflected in or suggested by these forward-looking statements are reasonable, it cannot provide assurance that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as: believe, expect, should, planned, will, may, intend, estimated, and potential, among others.

Contact Information

  • Contacts:

    Calypte Biomedical Corporation
    Richard Brounstein

    Market News First
    Angela Junell